BOSTON, Jan. 11, 2024 /PRNewswire/ -- SmartLabs, Inc., the leading provider of modular laboratory infrastructure and resourcing solutions, today announced that Brian Taylor has been appointed interim Chief Executive Officer effective January 5th. Taylor has been serving as SmartLabs' Executive Vice President of Biopharma Solutions since 2020, and as a 25-year veteran of the pharmaceutical industry, he brings a wealth of experience and an impressive skill set to his new position.

波士顿，2024年1月11日/PRNewswire/--模块化实验室基础设施和资源解决方案的领先供应商SmartLabs，Inc.今天宣布，Brian Taylor已被任命为临时首席执行官，自1月5日起生效。自2020年以来，泰勒一直担任SmartLabs生物制药解决方案执行副总裁，作为制药行业25年的老兵，他为自己的新职位带来了丰富的经验和令人印象深刻的技能。

In this critical leadership role, Taylor will oversee the development and provision of scientific service offerings for SmartLabs' partners engaged in programs of various sizes and scales, from early discovery to commercial manufacturing..

在这一关键的领导角色中，泰勒将监督SmartLabs合作伙伴的科学服务开发和提供，这些合作伙伴参与了从早期发现到商业制造等各种规模和规模的项目。。

Continue Reading

继续阅读

Brian Taylor, interim CEO, SmartLabs

Brian Taylor，SmartLabs临时首席执行官

'We are thrilled to welcome Brian as the new interim CEO of SmartLabs,' said Clayton Freeman, Portfolio Manager at ArrowMark Partners and SmartLabs board member. 'Brian's depth of experience across the industry and his track record of driving global strategic growth makes him the ideal leader to guide SmartLabs through its next phase of development.'.

ArrowMark Partners投资组合经理兼SmartLabs董事会成员克莱顿·弗里曼（ClaytonFreeman）说，我们很高兴欢迎布莱恩（Brian）出任SmartLabs新任临时首席执行官Brian在整个行业拥有丰富的经验，在推动全球战略增长方面有着良好的业绩记录，这使他成为指导SmartLabs进行下一阶段开发的理想领导者。”。

Taylor's expertise runs across all facets of biomanufacturing, having held leadership roles with established biopharmaceutical organizations. He joined SmartLabs from Zymergen, where he served as VP of Healthcare and played a pivotal role in driving the company's rapid growth. Earlier in his career, Taylor held various executive roles at GE Healthcare Life Sciences (now Cytiva, a Danaher company), where he led the Biomanufacturing Solutions business, designing and deploying turnkey single-use manufacturing solutions for mAb production that supported a wide range of customers globally..

泰勒的专业知识贯穿于生物制造的各个方面，曾在已建立的生物制药组织中担任领导角色。他从Zymergen加入SmartLabs，担任医疗保健副总裁，在推动公司快速增长方面发挥了关键作用。在职业生涯早期，泰勒曾在GE Healthcare Life Sciences（现为Cytiva，一家Danaher公司）担任过多个高管职位，领导生物制造解决方案业务，为单克隆抗体生产设计和部署交钥匙一次性制造解决方案，为全球范围内的广泛客户提供支持。。

'I am excited to accept this leadership opportunity at SmartLabs as we continue to innovate to improve how leading-edge science is developed and delivered to patients,' said Taylor. 'Our Universal Lab Framework enables companies to accelerate R&D timelines while saving significantly on upfront capital expenditures.

泰勒说：“我很高兴能在SmartLabs接受这一领导机会，因为我们将继续创新，改进前沿科学的开发和向患者提供的方式。”我们的通用实验室框架使公司能够加快研发时间表，同时大大节省前期资本支出。

I look forward to working with our exceptional SmartLabs team as we further develop our solutions offering to answer our customers' unique needs.'About SmartLabsFounded in 2015, SmartLabs offers the first integrated platform combining flexible lab infrastructure, operations, and scientific expertise.

我期待着与我们杰出的SmartLabs团队合作，进一步开发解决方案，以满足客户的独特需求关于SmartLabs成立于2015年，SmartLabs提供了第一个集成平台，结合了灵活的实验室基础设施、操作和科学专业知识。

Its Managed Research Centers allow companies to purchase private, enterprise-grade R&D infrastructure and manufacturing solutions 'as-a-service' without upfront capital costs. With headquarters in Boston and locations across the U.S., SmartLabs serves over 120 diverse biopharma and life sciences organizations.

其管理的研究中心允许公司购买私人、企业级研发基础设施和制造解决方案“即服务”，而无需预付资金成本。SmartLabs总部位于波士顿，遍布美国各地，为120多个不同的生物制药和生命科学组织提供服务。

For more information, visit www.smartlabs.com.SOURCE SmartLabs.

有关更多信息，请访问www.smartlabs.com.SOURCE smartlabs。